bintrafusp alfa

INTR@PID CLINICAL TRIALS™

Investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF-β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

INTR@PID™ CERVICAL 017[1] Active, Not Recruiting

ADVANCED/METASTATIC CERVICAL CANCER | PHASE 2 | 1 MONOTHERAPY

INTR@PID CERVICAL 017 (NCT04246489) is a phase 2, single-arm study evaluating bintrafusp alfa for the treatment of patients with advanced unresectable and/or metastatic cervical cancer who had disease progression with platinum-containing chemotherapy.*

Study design | Global

Advanced unresectable and/or metastatic cervical cancer N=146 → **Bintrafusp alfa** 1200 mg IV Q2W†

Primary endpoint: OR

Secondary endpoints: DOR, DRR, safety, PFS, OS, pharmacokinetics

Key inclusion criteria‡

- Participants must have advanced unresectable and/or metastatic cervical cancer and experienced disease progression with platinum-containing chemotherapy.* Participants must have an ECOG PS of 0 or 1 and not received checkpoint inhibitors

Key exclusion criteria‡

- Participants must not have interstitial lung disease or a history of pneumonitis that required steroids

*Platinum-containing chemotherapy may have been a systemic treatment for advanced unresectable, recurrent, persistent, or metastatic disease, or given in the adjuvant/neoadjuvant setting with disease progression or recurrence within 6 months of treatment completion. Patients who previously only received platinum as a radiosensitizer are not eligible. †Until confirmed disease progression, death, unacceptable toxicity, or study withdrawal. ‡For a full list of inclusion and exclusion criteria, please visit www.clinicaltrials.gov.

DOR, duration of response; DRR, durable response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; OR, objective response; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q2W, every 2 weeks; TGF-β, transforming growth factor β.

Reference: 1. ClinicalTrials.gov. Bintrafusp alfa monotherapy in platinum-experienced cervical cancer. https://clinicaltrials.gov/ct2/show/NCT04246489. Accessed February 4, 2021.



For more information, visit
www.intrapidclinicaltrials.com
www.clinicaltrials.gov

US-BIN-00065 | February 2021